European Patent Convention

Tonix Pharmaceuticals Announces Issuance of EU Patent Covering Intranasal Potentiated Oxytocin (TNX-1900) for the Treatment of Pain

Retrieved on: 
Wednesday, October 4, 2023
University of Geneva, Patent, Insulin resistance, Tonix Pharmaceuticals, Migraine, University, Magnesium, Prader–Willi syndrome, European Patent Office, INSERM, Feeding disorder, Oxytocin, IP, EPO, Patient, European Patent Convention, Pharmaceutical industry

CHATHAM, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that the European Patent Office (EPO) issued European Patent No. 3242676 to the Company on October 4, 2023. The patent, entitled “Magnesium-Containing Oxytocin Formulations and Methods of Use”, claims methods and compositions for treating pain, including migraine headaches, using intranasal magnesium-containing oxytocin formulations. This patent, excluding possible patent term extensions, is expected to provide Tonix with market exclusivity in the member states of the European Patent Office until 2036. The U.S. Patent and Trademark Office (USPTO) has previously issued U.S. Patents No. 9,629,894 and 11,389,473 which are expected to provide market exclusivity in the U.S. until 2036.

Key Points: 
  • CHATHAM, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that the European Patent Office (EPO) issued European Patent No.
  • The patent, entitled “Magnesium-Containing Oxytocin Formulations and Methods of Use”, claims methods and compositions for treating pain, including migraine headaches, using intranasal magnesium-containing oxytocin formulations.
  • This patent, excluding possible patent term extensions, is expected to provide Tonix with market exclusivity in the member states of the European Patent Office until 2036.
  • “We believe this European patent combined with the U.S. issuance provides a strong patent position for TNX-1900 as we move forward in clinical development for the treatment of chronic migraine,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals.

SciSparc Granted European Patent for its Core Technology

Retrieved on: 
Tuesday, October 3, 2023
Patent, Central nervous system, Disorder, N-Acylethanolamine, TEL, European Patent Convention, European Patent Office, Safety, Pharmaceutical industry, Cannabinoid

TEL AVIV, Israel, Oct. 03, 2023 (GLOBE NEWSWIRE) --  SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that The European Patent Office has granted it a new patent - European Application No. 16786064.2, title: Combinations of Cannabinoids and N-Acylethanolamines (the “Patent”). This Patent aligns with the Company's objective to increase the safety of cannabinoids treatments while maintaining their therapeutic effects.

Key Points: 
  • TEL AVIV, Israel, Oct. 03, 2023 (GLOBE NEWSWIRE) --  SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that The European Patent Office has granted it a new patent - European Application No.
  • 16786064.2, title: Combinations of Cannabinoids and N-Acylethanolamines (the “Patent”).
  • This Patent aligns with the Company's objective to increase the safety of cannabinoids treatments while maintaining their therapeutic effects.
  • With this grant, the Company has been granted this patent in the United States, Japan and Australia, supporting the innovation of SciSparc in its technologies.

Cellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants

Retrieved on: 
Monday, October 2, 2023
PLE, IP Australia, Radiation, Glioma, Intellectual property, Neoplasm, Lung cancer, Christian democracy, IP, Chinese, EPO, PDC, Patent, Patient, Melanoma, CIPO, European Patent Convention, Metastasis, European Patent Office, Glomus tumor, Identification, Canadian Intellectual Property Office, Isolation, Medical imaging, Pharmaceutical industry, Cancer

FLORHAM PARK, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced significant advancements to its global intellectual property (IP) portfolio.

Key Points: 
  • FLORHAM PARK, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced significant advancements to its global intellectual property (IP) portfolio.
  • This patent significantly enhances the use of iopofosine I 131 for treating various cancers, including gliomas, lung cancer, melanoma, and more, with a focus on cancer stem cells.
  • The Canadian Intellectual Property Office (CIPO), the Australian Patent Office (IP Australia) and the EPO have granted patent number 17814042.2 for "Phospholipid Ether Analogs for the Identification and Isolation of Circulating Tumor Cells".
  • “The expanded protection in these key global regions supplements our existing patent portfolio and the coverage with these patents we have already obtained in the US and other territories.

Medigene AG Secures European Patent for its PD1-41BB Costimulatory Switch Protein

Retrieved on: 
Wednesday, September 27, 2023
Planegg, European patent law, European Patent Office, FSE, EP3, Patent, Patient, European Patent Convention, CSP, Safety, Pharmaceutical industry

---  end of press release  ---

Key Points: 
  • Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued a patent (EP3 433 269) by the European Patent Office protecting its PD1-41BB costimulatory switch protein (CSP) technology.
  • Medigene’s PD1-41BB CSP was developed by its partner Helmholtz Munich and is exclusively licensed to Medigene.
  • “We are delighted to have been granted the European Patent for our PD1-41BB CSP, one of the key technologies of Medigene’s End-to-End (E2E) Platform.
  • This complements our PD1-41BB IP-portfolio with similar patents already granted in the United States, China and Japan, and strengthens our patent portfolio worldwide,” said Selwyn Ho, CEO at Medigene AG.

Poxel Reports Financial Results for First Half 2023 and Provides a Corporate Update

Retrieved on: 
Tuesday, September 26, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Diabetes, ULF, Adrenoleukodystrophy, Prescription, Plasma, JPY, Patent, Patient, Serono, Merck, R, Estonia, POC, Pioglitazone, Sumitomo Group, Disease, Male, NASH, Pharmacokinetics, Sumitomo Pharma, EPO, Fatty liver disease, Leukodystrophy, Marshal of France, Rare, Kidney, Conference, Safety, Abstract, DPP4, ALD, JDS, Merck Serono, European Patent Office, Biomarker, DSM-IV codes, AMN, IRIS, Scientific communication, United States patent law, SGLT2, VLCFA, EUR, European Patent Convention, Pharmacology, TZD, Pharmaceutical industry, Medical device, Imeglimin, Euronext

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its financial results for the period ended June 30, 2023 and provided a corporate update.

Key Points: 
  • POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its financial results for the period ended June 30, 2023 and provided a corporate update.
  • For the Sumitomo Pharma FY 2023, as a conservative assumption in line with Sumitomo Pharma’s forecast, Poxel expects to receive 8% royalties on TWYMEEG net sales.
  • On July 5th, Poxel was chosen as the winner of the 2023 edition of the I-nov contest for its program in ALD.
  • This recently issued patent provides additional protection through 2041, with the potential for an additional 5 years through patent term extension.

NanoString Comments on Unified Patent Court Order

Retrieved on: 
Tuesday, September 19, 2023
Research, Professional Services, Patent Law, Technology, Genetics, Health Technology, Science, Legal, Biotechnology, Other Technology, Other Science, Health, Genomics, SMI, UPC, RNA, Harvard University, Bangladesh Technical Education Board, Patent, Patient, 10x Genomics, European, European Patent Convention, NanoString Technologies, United Kingdom, Genome, EU

NanoString remains steadfast in our commitment to defend the scientific community’s access to our products and researchers’ scientific freedom to select the platforms that best advance their research.

Key Points: 
  • NanoString remains steadfast in our commitment to defend the scientific community’s access to our products and researchers’ scientific freedom to select the platforms that best advance their research.
  • We do not yet have a date for those hearings.”
    Today’s order relates to European Patent 4108782B1 (the “‘782 Patent”).
  • The UPC announced that it would issue a decision in the preliminary injunction matter related to European Patent 2794928B1 (the “‘928 Patent”) on Tuesday, October 10, 2023.
  • NanoString management is reiterating its guidance for fiscal year 2023 total revenue of between $175 -$185 million.

10x Wins Injunction From Unified Patent Court Banning Sales of NanoString's CosMx Products in Europe

Retrieved on: 
Tuesday, September 19, 2023
Patent, NanoString Technologies, Genomics, Federal Patent Court (Germany), 10x Genomics, SMI, UPC, Palatine Higher Regional Court, Research, RNA, Science, Invention, Rosenbergia xenium, District court, Investment, Patient, European, Unified Patent Court, European Patent Convention, Court, Health, Douglas v. U.S. District Court ex rel Talk America, Disease, Alex Cartana, Microscope

PLEASANTON, Calif., Sept. 19, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that the European Unified Patent Court ("UPC") issued a preliminary injunction against NanoString Technologies, Inc. (Nasdaq: NSTG) for infringing European Patent 4 108 782 B1 ("the EP 782 patent," docket No 459746/2023). The preliminary injunction, issued by a panel of four judges with both legal and technical expertise, prevents NanoString from selling or providing services using its CosMx Spatial Molecular Imager (SMI) instruments and CosMx reagents for RNA detection in all 17 countries of the UPC.

Key Points: 
  • "A patent holder must meet a very high standard to win a preliminary injunction," added Whitaker.
  • "Two separate courts have now found that NanoString's CosMx products infringe two different 10x patents, and three separate courts have preliminarily found the 10x patents valid in the asserted scope.
  • The full opinions of the Unified Patent Court will be posted here when available: 10xgen.com/munich-spatial-news .
  • 10x also intends to seek an injunction against sales of GeoMx as well as ongoing damages.

EQS-News: BRAIN Biotech AG: BRAIN Biotech AG’s Akribion Genomics technology receives patent approval for its groundbreaking nuclease G-dase E®

Retrieved on: 
Saturday, September 16, 2023
CRISPR, BRAIN, Genomics, European Patent Office, Enzyme, Toxicity, Research, Cell, Patent, European Patent Convention, Bacteria, Family, Antibiotics, Pharmaceutical industry

Zwingenberg, Germany, 14 September 2023 – BRAIN Biotech AG today announced that the European Patent Office has issued a new patent covering BRAIN’s G-dase E® nucleases as a composition of matter patent.

Key Points: 
  • Zwingenberg, Germany, 14 September 2023 – BRAIN Biotech AG today announced that the European Patent Office has issued a new patent covering BRAIN’s G-dase E® nucleases as a composition of matter patent.
  • BRAIN Biotech's Akribion Genomics team has developed a novel family of CRISPR nucleases “G-dases” with strong activity in various organisms, including bacteria and mammalian cells.
  • The Akribion Genomics team develops groundbreaking CRISPR nucleases into a new class of genetics-based cancer therapies and advanced genome editing tools, today powered by the BRAIN Biotech AG BioIncubator.
  • The Akribion Genomics team and BRAIN Biotech management remain in active discussions with potential financial and strategic partners to accelerate therapeutic applications with a focus on oncology.

RedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®)

Retrieved on: 
Tuesday, September 5, 2023
Patent, European Patent Office, Vomiting, European Patent Convention, Nausea, Ebola, Pharmaceutical industry, USPTO

TEL-AVIV, Israel and RALEIGH, N.C., Sept. 5, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) had issued a Notice of Allowance for a new opaganib[1] patent covering sphingosine kinase 2 inhibition treatment for Ebola virus disease, supporting opaganib pro tection until October 2035. The Company also announced that the European Patent Office has granted RHB-102 (BEKINDA)[2] a new patent, covering ondansetron extended-release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms. This new patent is expected to provide protection of RHB-102 across multiple indications until March 2035.

Key Points: 
  • USPTO issues Notice of Allowance for a new opaganib patent covering sphingosine kinase 2 inhibition treatment for Ebola virus disease, supporting opaganib protection until October 2035
    Additionally, European Patent Office grants new RHB-102 patent covering ondansetron extended-release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms, providing protection of RHB-102 across multiple indications until March 2035
    TEL-AVIV, Israel and RALEIGH, N.C., Sept. 5, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) had issued a Notice of Allowance for a new opaganib[1] patent covering sphingosine kinase 2 inhibition treatment for Ebola virus disease, supporting opaganib pro tection until October 2035.
  • The Company also announced that the European Patent Office has granted RHB-102 (BEKINDA)[2] a new patent, covering ondansetron extended-release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms.
  • This new patent is expected to provide protection of RHB-102 across multiple indications until March 2035.

Poxel Reports Cash and Revenue for the Second Quarter and First Half 2023 and Provides Corporate Update

Retrieved on: 
Wednesday, August 30, 2023
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Diabetes, ULF, Senior, Adrenoleukodystrophy, Prescription, Plasma, JPY, Patent, Patient, Serono, Merck, R, Estonia, POC, Pioglitazone, Sumitomo Group, Disease, Male, NASH, Pharmacokinetics, USD, EPO, Fatty liver disease, Leukodystrophy, Marshal of France, Rare, Kidney, Conference, Safety, Abstract, DPP4, ALD, JDS, Merck Serono, European Patent Office, Biomarker, DSM-IV codes, Communication, AMN, IRIS, Scientific communication, Sumitomo Pharma, United States patent law, SGLT2, VLCFA, European Patent Convention, Pharmacology, TZD, Pharmaceutical industry, Medical device, Cryptocurrency, Imeglimin, EUR, Euronext

These factors have resulted in a much higher increase in demand for TWYMEEG than expected by Sumitomo, and thus inventories are temporarily tight.

Key Points: 
  • These factors have resulted in a much higher increase in demand for TWYMEEG than expected by Sumitomo, and thus inventories are temporarily tight.
  • For the Sumitomo FY 2023, as a conservative assumption in line with Sumitomo’s forecast, Poxel expects to receive 8% royalties on TWYMEEG net sales.
  • On July 5th, Poxel was chosen as the winner of the 2023 edition of the I-nov contest for its program in ALD.
  • As of June 30, 2023, cash and cash equivalents were EUR 7.6 million (USD 8.2 million), as compared to EUR 13.1 million (USD 14.0 million) as of December 31, 2022.